multiple myeloma articles & resources on Made-in-China.com

Outcomes for Patients Are Receiving Allogeneic Transplants

Feb 7, 2014

For the fourth consecutive year, outcomes for patients receiving allogeneic transplants through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) have been shown to be significantly better than would be ...

Tags: CIBMTR, RPCI, Blood, Marrow

Senesco Technologies Reported The Treatment of The First Patient

Oct 28, 2013

Senesco Technologies reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its ...

Tags: Senesco, Clinical Trial

NDA for The Investigational Oral BTK Inhibitor,Ibrutinib,Has Been Accepted by The US FDA

Sep 2, 2013

Clinical-stage biopharmaceutical company Pharmacyclics' new drug application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been accepted by the US FDA for two B-cell malignancy indications. ...

Tags: Solvay Group, Medicine

Purchase Price of The Transaction Expected to Be Closed by The Beginning Is $10.4bn

Aug 27, 2013

Biotechnology company Amgen has reached a deal to buy all outstanding shares of California-based Onyx Pharmaceuticals for $125 per share in cash. The purchase price of the transaction that is expected to be closed by the beginning of ...

Tags: Amgen, Onyx Pharmaceuticals

Celgene's Pomalidomide Oral Anti-cancer Therapy Has Won European Commission Approval

Aug 13, 2013

Celgene International's oral anti-cancer therapy Pomalidomide has won European Commission approval as treatment for patients with relapsed/refractory multiple myeloma (rrMM), a rare form of blood cancer, in combination with dexamethasone. ...

Tags: Anti-Cancer Therapy

SGNT Has Received The Approval of Zoledronic Acid Injection 4mg/100ml

Aug 9, 2013

Sagent Pharma (SGNT) has received the approval of Zoledronic Acid Injection 4mg/100ml, the generic form of the bisphosphonate Zometa, to be packed in a ready-to-use premix IV bag. The new packaging for Zoledronic Acid Injection features ...

Tags: Sagent, Premix Bag, Zoledronic Acid

Curis Has Secured US Patent Protecting Intellectual Property Rights

Jun 24, 2013

Oncology-focused drug development company Curis has secured US patent protecting intellectual property rights of its phosphoinositide 3-kinase (PI3K) - histone deacetylase (HDAC) inhibitor, CUDC-907. The patent covers the method of ...

Tags: Health&Medicine, Curis, US

The EMA Committee for CHMP Has Adopted a Positive Opinion

Jun 4, 2013

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Celgene International's oral anti-cancer therapy Pomalidomide. The positive results from the MM-003 study of ...

Tags: Health, Medicine

Point-of-Care Diagnostic Device for Multiple Myeloma Is Launched by Serascience

Apr 5, 2013

Serascience, a joint venture between Abingdon Health and the University of Birmingham, has introduced a proprietary point-of-care diagnostic device for multiple myeloma. Designed to aid in the diagnosis of myeloma and monitor relapse and ...

Tags: Diagnostic Device, Multiple Myeloma, Medicine

Genmab Has Obtained FDA Fast Track Designation in Double Refractory Multiple Myeloma

Apr 4, 2013

Biotechnology company Genmab has obtained FDA fast track designation in double refractory multiple myeloma for daratumumab. As per the designation, the human CD38 monoclonal antibody Daratumumab is suitable for multiple myeloma patients ...

Tags: Genmab Daratumumab, FDA, Fast Track Designation

Dr. Reddy's Laboratories Has Launched Zoledronic Acid Injection

Mar 7, 2013

India-based global pharmaceutical company Dr. Reddy's Laboratories has launched Zoledronic Acid injection (4 mg/5 mL), following the approval of its abbreviated new drug application (ANDA) from the Food and Drug Administration, in the US. ...

Tags: pharmaceutical company, pharmaceutical services, pharmaceutical

FDA Has Approved a New Drug Named Pomalyst (Pomalidomide) for Patients

Feb 18, 2013

The US Food and Drug Administration (FDA) has approved a new drug named Pomalyst (pomalidomide) for patients who received and did not respond to prior cancer therapies. Pomalyst, the third drug in a class of immunomodulatory agents ...

Tags: FDA, new drug, Pomalyst

Birmingham Won "The Open Collaboration Award" at The Lord Stafford Awards Ceremony

Jan 22, 2013

A joint venture company between Abingdon Health and the University of Birmingham won ‘The Open Collaboration Award’ at the Lord Stafford Awards ceremony and dinner held in November. The primary objective of Bioscience Ventures ...

Tags: life sciences, medical diagnosis products, medical diagnostics science

Coronado Biosciences Received Notice of Allowance for CNDO-109

Dec 5, 2012

Coronado Biosciences has received notice of allowance for US patent application covering CNDO-109, from the US Patent and Trademark Office (USPTO). The patent is entitled, Method for activating natural killer cells by tumor cell ...

Tags: CNDO-109, cancer cells, AML

Janssen, Genmab Has Executed a License and Development Agreement

Nov 29, 2012

Janssen Biotech, a Johnson & Johnson company, has executed a license and development agreement for an investigational anti-cancer agent, daratumumab (HuMax-CD38), with Genmab. Daratumumab is a human CD38 monoclonal antibody which is ...

Tags: Daratumumab License, license and development agreement, anti-cancer

multiple myeloma

Related Products